Government announces grant recipients, new funding for NSW businesses

Research commercialisation includes initiatives in biosciences.

The government of New South Wales (NSW) in Australia has introduced a new fund for emerging technologies worth over $14m (AU$20m) whilst announcing the recipients of two research commercialisation programmes.

The new funding will be for high-tech innovations across various branches of science, helping NSW startups turn their research into actual products, services, or systems. 

Meanwhile the separate Biosciences Fund and RNA Pipeline Grants have named their respective grant recipients. All G, HydGene Renewables, Number 8 Bio, and Swan Genomics were selected for the AU$4.75m Biosciences Fund; Platypus Bio and Vaxosome for RNA, which is a AU$6m pot.

"[The] Biosciences Fund recipients are developing unique solutions for infant formula, green hydrogen for chemical applications, livestock emissions reduction, and low-cost genomic sequencing," noted Minister for Innovation, Science and Technology Anoulack Chanthivong.

"Meanwhile, the RNA Pipeline Grants recipients are developing world-leading therapeutics that could save lives – a highly targeted treatment for cancer, including acute myeloid leukaemia, and an mRNA tuberculosis vaccine offering improved immune protection over current treatments.

"The RNA Pipeline Grants also serve an important role in developing RNA capabilities that will make the most of our new RNA Manufacturing Facility, which will open soon.

"I'm also excited to announce the launch of our newest program supporting innovation in NSW, the Emerging Technologies Commercialisation Fund."

Preliminary applications for the Emerging Technologies Commercialisation Fund will close on 29 April.